Radium-223 behandling af knoglemetastaser ved kastrationsrefraktær prostatacancer
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Radium-223 behandling af knoglemetastaser ved kastrationsrefraktær prostatacancer. / Mortensen, Jann; Højgaard, Liselotte.
I: Ugeskrift for Laeger, Bind 176, Nr. 30, 21.07.2014, s. 1399-1402.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Radium-223 behandling af knoglemetastaser ved kastrationsrefraktær prostatacancer
AU - Mortensen, Jann
AU - Højgaard, Liselotte
PY - 2014/7/21
Y1 - 2014/7/21
N2 - The alpha emitter Radium-223 ((22)3Ra-Cl2) is a bone-seeking radionuclide studied as a new treatment for patients with bone metastases from hormone refractory prostate cancer. More than 1,000 patients have been included in clinical phase I-III tests showing significant reduction in alkaline phosphatase- and PSA level and prolonged survival. Adverse events are usually mild to moderate and comprise gastrointestinal and myelotoxic symp-toms. Intravenously administered (22)3Ra-Cl2 (half-life 11.4 days) will likely be given every four weeks for six treatments to out-patients.
AB - The alpha emitter Radium-223 ((22)3Ra-Cl2) is a bone-seeking radionuclide studied as a new treatment for patients with bone metastases from hormone refractory prostate cancer. More than 1,000 patients have been included in clinical phase I-III tests showing significant reduction in alkaline phosphatase- and PSA level and prolonged survival. Adverse events are usually mild to moderate and comprise gastrointestinal and myelotoxic symp-toms. Intravenously administered (22)3Ra-Cl2 (half-life 11.4 days) will likely be given every four weeks for six treatments to out-patients.
M3 - Tidsskriftartikel
C2 - 25292232
VL - 176
SP - 1399
EP - 1402
JO - Ugeskrift for Laeger
JF - Ugeskrift for Laeger
SN - 0041-5782
IS - 30
ER -
ID: 137378962